Effect of metformin on hepatic glucose production in Japanese patients with type 2 diabetes mellitus

Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic innervations in central nervous system that results in decrease of postprandial glucose. Bromocriptine decreases hepatic glucose production and increases insulin secretion and muscle insulin sensitivity. This article reviews experimental and clinical data on the use of bromocriptine for treatment of type 2 diabetes mellitus

Download Full-text

Impaired suppression of endogenous glucose production in lean Japanese patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2011.03.002 ◽

2011 ◽

Vol 93 (1) ◽

pp. e1-e2 ◽

Cited By ~ 2

Author(s):

Mitsuyoshi Takahara ◽

Hideaki Kaneto ◽

Naoto Katakami ◽

Taka-aki Matsuoka ◽

Munehide Matsuhisa ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glucose Production ◽

Japanese Patients ◽

Endogenous Glucose Production ◽

Endogenous Glucose

Download Full-text

Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of Type 2 diabetes mellitus

Biochemical Journal ◽

10.1042/bj3490657 ◽

2000 ◽

Vol 349 (3) ◽

pp. 657-665 ◽

Cited By ~ 86

Author(s):

Mark J. HOLNESS ◽

Maria L. LANGDOWN ◽

Mary C. SUGDEN

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glucose Intolerance ◽

Low Birthweight ◽

Hepatic Glucose Production ◽

Subsequent Development ◽

Glucose Production ◽

Glucose Disposal

There is increasing epidemiological evidence in humans which associates low birthweight with later metabolic disorders, including insulin resistance and glucose intolerance. There is evidence that nutritional and hormonal factors (e.g. maternal protein restriction, exposure to excess maternal glucocorticoids) markedly influence intra-uterine growth and development. A picture is also emerging of the biochemical and physiological mechanisms that may underlie these effects. This review focuses on recent research directed towards understanding the molecular basis of the relationship between indices of poor early growth and the subsequent development of glucose intolerance and Type 2 diabetes mellitus using animal models that attempt to recreate the process of programming via an adverse intra-uterine or neonatal environment. Emphasis is on the chain of events and potential mechanisms by which adverse adaptations affect pancreatic-β-cell insulin secretion and the sensitivity to insulin of key metabolic processes, including hepatic glucose production, skeletal-muscle glucose disposal and adipose-tissue lipolysis. Unravelling the molecular details involved in metabolic programming may provide new insights into the pathogenesis of impaired glucoregulation and Type 2 diabetes.

Download Full-text

Large-Scale Cross-Sectional Study of the Problem Areas in Diabetes Survey among Japanese Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db18-2393-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2393-PUB

Author(s):

KENICHIRO TAKAHASHI ◽

MINORI SHINODA ◽

RIKA SAKAMOTO ◽

JUN SUZUKI ◽

TADASHI YAMAKAWA ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Large Scale ◽

Japanese Patients ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Diabetes Survey

Download Full-text

Faculty Opinions recommendation of A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727146123.793527044 ◽

2017 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Diabetic Nephropathy ◽

Japanese Patients ◽

Randomized Controlled Study ◽

Controlled Study ◽

Randomized Controlled

Download Full-text

Comparative effects of insulin glulisine and lispro on postprandial plasma glucose and lipid profile in Japanese patients with type 2 diabetes mellitus

Diabetology International ◽

10.1007/s13340-020-00475-1 ◽

2020 ◽

Author(s):

Mika Yamada ◽

Jinya Suzuki ◽

Takahiro Nakaya ◽

Mai Ichikawa ◽

Katsushi Yamamoto ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Lipid Profile ◽

Plasma Glucose ◽

Japanese Patients ◽

Postprandial Plasma Glucose ◽

Insulin Glulisine

Download Full-text

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study

BMJ Open ◽

10.1136/bmjopen-2018-025806 ◽

2019 ◽

Vol 9 (3) ◽

pp. e025806 ◽

Cited By ~ 21

Author(s):

Rimei Nishimura ◽

Haruka Kato ◽

Koichi Kisanuki ◽

Akinori Oh ◽

Shinzo Hiroi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Drug Class ◽

Japanese Patients ◽

Medical Data ◽

Treatment Patterns ◽

Administrative Claims ◽

Antidiabetic Drug

ObjectiveTo determine real-world trends in antidiabetic drug use, and persistence and adherence, in Japanese patients with type 2 diabetes mellitus (T2DM).DesignRetrospective evaluation of administrative claims data (2011–2015) using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases.SettingAnalysis of two administrative claims databases for Japanese patients with T2DM.ParticipantsAdults (aged ≥18 years) with an International Classification of Diseases, 10th Revision code of T2DM and at least one antidiabetic drug prescription.Main outcome measuresTreatment patterns in untreated (UT) or previously treated (PT) patients receiving antidiabetic therapy; persistence with treatment at 12 months; adherence to treatment at 12 months.Results40 908 and 90 421 patients were included from the JMDC and MDV databases, respectively. The most frequently prescribed therapy at the index (first prescription) date was dipeptidyl peptidase-4 inhibitor (DPP-4i) in UT patients (JMDC: 44.0%, MDV: 54.8%) and combination therapy in PT patients (74.6%, 81.1%). Most common combinations were DPP-4i plus: biguanide (BG; 11.4%, 10.9%), sulfonylurea (SU; 8.4%, 11.0%) or BG+SU (7.8%, 9.1%). In UT or PT patients from either database whose index prescription was for any antidiabetic drug class(es) other than DPP-4i, the most frequent add-on or switch was to DPP-4i. 12-month persistence with index monotherapy was highest with DPP-4i and BG. Adherence was high (≥80%) for all monotherapy schedules, except insulin and glucagon-like peptide-1 agonist, and for the five most frequent two-drug and three-drug combinations. Persistence was greater in elderly UT patients and in those receiving ≤5 medications, but comparatively worse in UT patients with ≥3 index antidiabetic drug classes.ConclusionsThe findings indicate that DPP-4i is the most commonly used antidiabetic drug class in Japanese patients with T2DM, and persistence and adherence to this antidiabetic drug class are high.

Download Full-text